Replimune Group Ownership | Who Owns Replimune Group?
Replimune Group Ownership Summary
Replimune Group is owned by 25.84% institutional investors, 4.18% insiders, and 69.98% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 14.06% of REPL shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 6.15% of its assets in Replimune Group shares.
REPL Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Replimune Group | 25.84% | 4.18% | 69.98% |
| Sector | Healthcare Stocks | 57.38% | 9.40% | 33.23% |
| Industry | Biotech Stocks | 68.91% | 8.92% | 22.17% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Baker bros. advisors lp | 11.05M | 14.06% | $133.76M |
| Price t rowe associates inc /md/ | 10.96M | 13.95% | $132.76M |
| Fcpm iii services b.v. | 4.87M | 7.31% | $43.80M |
| Blackrock funding, inc. /de | 5.57M | 7.08% | $67.41M |
| Blackrock | 4.71M | 7.08% | $42.42M |
| Redmile group | 4.91M | 6.24% | $59.41M |
| Vanguard group | 3.60M | 4.58% | $43.55M |
| Sofinnova investments | 3.15M | 4.01% | $38.14M |
| Omega fund management | 2.46M | 3.70% | $22.15M |
| Tang capital management | 2.70M | 3.44% | $32.70M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Omega fund management | 2.46M | 16.41% | $22.15M |
| Fcpm iii services b.v. | 4.87M | 6.46% | $43.80M |
| Redmile group | 4.91M | 4.14% | $59.41M |
| Nan fung group | 321.75K | 3.33% | $3.90M |
| Sofinnova investments | 3.15M | 2.78% | $38.14M |
| Tang capital management | 2.70M | 2.16% | $32.70M |
| Velan capital investment management lp | 181.37K | 1.90% | $2.20M |
| Bioimpact capital | 950.00K | 1.63% | $11.50M |
| Rosalind advisors | 260.00K | 1.61% | $3.15M |
| Baker bros. advisors lp | 11.05M | 1.43% | $133.76M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Sofinnova investments | 3.15M | 2.78% | 3.10M |
| Boxer capital | 1.54M | 0.73% | 1.54M |
| Tang capital management | 2.70M | 2.16% | 1.50M |
| Rtw investments, lp | 1.13M | 0.16% | 1.13M |
| Price t rowe associates inc /md/ | 10.96M | 0.02% | 1.08M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| State street | 1.16M | 0.00% | -5.33M |
| Atlas venture life science advisors | - | - | -2.10M |
| Braidwell lp | 1.48M | 0.53% | -1.59M |
| Camber capital management lp | - | - | -1.35M |
| Jefferies financial group | - | - | -1.00M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Boxer capital | 1.54M | 0.73% | 1.54M | $13.83M |
| Rtw investments, lp | 1.13M | 0.16% | 1.13M | $10.20M |
| Bioimpact capital | 950.00K | 1.63% | 950.00K | $11.50M |
| Marshall wace, llp | 896.18K | 0.01% | 896.18K | $10.85M |
| Artisan partners limited partnership | 611.01K | 0.01% | 611.01K | $7.40M |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -8.00 |
| Global retirement partners | -32.00 |
| Riggs asset managment | -58.00 |
| Capital performance advisors llp | -76.00 |
| Truvestments capital | -80.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 91 | -38.10% | 20,304,371 | -70.81% | 25 | 0.33% | 55 | -30.38% | 17 | -56.41% |
| Sep 30, 2024 | 147 | -2.65% | 69,570,682 | -1.86% | 88 | 0.84% | 80 | -8.05% | 39 | -17.02% |
| Jun 30, 2024 | 150 | -2.60% | 70,892,178 | 6.49% | 106 | 1.07% | 86 | 3.61% | 47 | 20.51% |
| Mar 31, 2024 | 154 | 4.76% | 66,572,511 | 0.83% | 99 | 1.02% | 83 | -10.75% | 39 | 21.88% |
| Dec 31, 2023 | 147 | 0.68% | 66,021,205 | 16.25% | 99 | 1.35% | 93 | 38.81% | 32 | -21.95% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| US Small-Cap Growth II Equity Comp | 4.73M | 6.15% | 337.32K |
| T. Rowe Price New Horizons | 4.73M | 6.15% | - |
| T. Rowe Price Integrated US SmCapGrEq | 2.96M | 3.85% | 1.63M |
| Vanguard Total Stock Mkt Idx Inv | 1.99M | 2.58% | - |
| T. Rowe Price Health Sciences | 1.72M | 2.23% | -4.53K |
| iShares Russell 2000 ETF | 1.60M | 2.07% | -31.24K |
| T. Rowe Price Integrated US Sm Gr Eq | 1.48M | 1.93% | - |
| T. Rowe Price New Horizons Tr-Z | 1.28M | 1.66% | 274.81K |
| Vanguard Institutional Extnd Mkt Idx Tr | 888.40K | 1.15% | 281.00 |
| SPDR® S&P Biotech ETF | 825.98K | 1.07% | 6.26K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 16, 2024 | Patel Sushil | Chief Executive Officer | Sell | $124.20K |
| Nov 18, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | $78.11K |
| Nov 18, 2024 | Sarchi Christopher | Chief Commercial Officer | Sell | $56.13K |
| Aug 16, 2024 | Hill Emily Luisa | Chief Financial Officer | Sell | $90.99K |
| Jun 07, 2024 | Xynos Konstantinos | Chief Medical Officer | Sell | $119.11K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | - |
| 2024 Q4 | - | 3 |
| 2024 Q3 | - | 1 |
| 2024 Q2 | - | 8 |
| 2023 Q4 | - | 2 |
REPL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools